Literature DB >> 14689087

[Hypophyseal coma].

B L Herrmann1, K Mann.   

Abstract

Pituitary coma is a rare case of emergency and primarily due to ACTH and TSH deficiency. Pituitary coma occurs more often in patients with well-known pituitary deficiency than in patients with intrasellar tumor. Clinical manifestations are hypotonia, bradycardia, decreased skin and nipple pigmentation, muscle weakness, vomitus, nausea, obstipation, hypothermia, and hypoventilation. A postpartal agalactia is often the first sign of Sheehan's syndrome. Unlike primary adrenal insufficiency (Addison's disease) ACTH deficiency does not cause hyperpigmentation, hyperkalemia, or salt loss. The suspicion of pituitary coma requires replacement with 100 mg hydrocortisone iv, 200 mg hydrocortisone iv/24 h, 500 micro g levothyroxine iv and fluid substitution. Since thyroxine accelerates the degradation of cortisol and can precipitate adrenal crisis in patients with limited pituitary reserve, hydrocortisone replacement should always precede levothyroxine therapy. ACTH stimulation test, CRH stimulation test and insulin tolerance test (optional) should be performed after therapeutic compensation to determine pituitary function.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14689087     DOI: 10.1007/s00108-003-1047-9

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

1.  No advantage of the new combined octreotide-GHRH test over established GH-stimulation tests in the diagnosis of growth hormone deficiency (GHD) in adults.

Authors:  F Schütz; C Wüster; P Heilmann; R Ziegler; P Hadji
Journal:  Clin Endocrinol (Oxf)       Date:  2000-12       Impact factor: 3.478

2.  Dehydroepiandrosterone replacement in women with adrenal insufficiency.

Authors:  W Arlt; F Callies; J C van Vlijmen; I Koehler; M Reincke; M Bidlingmaier; D Huebler; M Oettel; M Ernst; H M Schulte; B Allolio
Journal:  N Engl J Med       Date:  1999-09-30       Impact factor: 91.245

Review 3.  Hypopituitarism in langerhans cell histiocytosis: seven cases and literature review.

Authors:  D Modan-Moses; M Weintraub; J Meyerovitch; G Segal-Lieberman; B Bielora
Journal:  J Endocrinol Invest       Date:  2001-09       Impact factor: 4.256

Review 4.  Clinical review 62: Laboratory assessment of adrenal insufficiency.

Authors:  S K Grinspoon; B M Biller
Journal:  J Clin Endocrinol Metab       Date:  1994-10       Impact factor: 5.958

5.  Hypopituitarism following traumatic brain injury and aneurysmal subarachnoid hemorrhage: a preliminary report.

Authors:  D F Kelly; I T Gonzalo; P Cohan; N Berman; R Swerdloff; C Wang
Journal:  J Neurosurg       Date:  2000-11       Impact factor: 5.115

Review 6.  Disorders of the aldosterone synthase and steroid 11beta-hydroxylase deficiencies.

Authors:  M Peter; J M Dubuis; W G Sippell
Journal:  Horm Res       Date:  1999

7.  Isolated ACTH deficiency with transitory GH deficiency.

Authors:  Z Hochberg; D Hardoff; D Atias; A Spindel
Journal:  J Endocrinol Invest       Date:  1985-02       Impact factor: 4.256

Review 8.  Dopamine receptor agonists for treating prolactinomas.

Authors:  Annamaria Colao; Antonella di Sarno; Rosario Pivonello; Carolina di Somma; Gaetano Lombardi
Journal:  Expert Opin Investig Drugs       Date:  2002-06       Impact factor: 6.206

9.  Retesting young adults with childhood-onset growth hormone (GH) deficiency with GH-releasing-hormone-plus-arginine test.

Authors:  G Aimaretti; C Baffoni; S Bellone; L Di Vito; G Corneli; E Arvat; L Benso; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  2000-10       Impact factor: 5.958

Review 10.  Consequences of growth hormone deficiency in adults and the benefits and risks of recombinant human growth hormone treatment. A review paper.

Authors:  T Rosén; G Johannsson; J O Johansson; B A Bengtsson
Journal:  Horm Res       Date:  1995
View more
  1 in total

Review 1.  [Pituitary coma].

Authors:  P H Kann
Journal:  Med Klin Intensivmed Notfmed       Date:  2012-08-23       Impact factor: 0.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.